Tyler Lipschultz - 05 Jan 2023 Form 4 Insider Report for SeaSpine Holdings Corp

Reporting relationship: SVP, Orthobiologics and BD
Issuer ticker: N/A
Reported as of: 05 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jan 2023, 18:18:04 UTC
Prior SEC filing: 03 Jan 2023
Next SEC filing: 08 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/Paul Benny, Attorney-in-Fact for Tyler Lipschultz

Key filing fact

Tyler Lipschultz filed Form 4 for SeaSpine Holdings Corp on 09 Jan 2023.

Key facts

This page summarizes Tyler Lipschultz's Form 4 filing for SeaSpine Holdings Corp.
10 reported transactions and 9 derivative rows are listed below.
Accepted by SEC: 09 Jan 2023, 18:18.

Change

Previous filing in this sequence was filed on 03 Jan 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SPNE transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -131,284
Change %: -100%
Price
Shares after: 0
Date: 05 Jan 2023
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SPNE transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
Shares: -12,970
Change %: -100%
Price
Shares after: 0
Date: 05 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,970
Exercise price
Footnotes: F2, F3, F4

SPNE transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
Shares: -33,977
Change %: -100%
Price
Shares after: 0
Date: 05 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 33,977
Exercise price: $0.000000
Footnotes: F2, F5, F6

SPNE transaction Derivative

Employee Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -60,000
Change %: -100%
Price
Shares after: 0
Date: 05 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 60,000
Exercise price: $15.68
Footnotes: F7, F8

SPNE transaction Derivative

Employee Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -64,599
Change %: -100%
Price
Shares after: 0
Date: 05 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 64,599
Exercise price: $14.19
Footnotes: F9, F10

SPNE transaction Derivative

Employee Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -35,636
Change %: -100%
Price
Shares after: 0
Date: 05 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,636
Exercise price: $18.24
Footnotes: F11, F12

SPNE transaction Derivative

Employee Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -27,873
Change %: -100%
Price
Shares after: 0
Date: 05 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 27,873
Exercise price: $12.01
Footnotes: F13, F14

SPNE transaction Derivative

Employee Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -6,089
Change %: -100%
Price
Shares after: 0
Date: 05 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,089
Exercise price: $9.93
Footnotes: F15, F16

SPNE transaction Derivative

Employee Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -16,196
Change %: -100%
Price
Shares after: 0
Date: 05 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,196
Exercise price: $16.86
Footnotes: F17, F18

SPNE transaction Derivative

Employee Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -21,236
Change %: -100%
Price
Shares after: 0
Date: 05 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 21,236
Exercise price: $15.00
Footnotes: F19, F20

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Tyler Lipschultz is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 20 footnotes

Footnote F1

Disposed of pursuant to the Agreement and Plan of Merger by and among the issuer, SeaSpine Holdings Corporation, which became effective on January 5, 2023, in exchange for 54,653 Orthofix MedicalInc. ("Orthofix") ordinary shares having a market value of $22.76 per share at the effective time of the merger.

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

Footnote F3

The restricted stock units vest in three equal installments on each of January 28, 2022, 2023 and 2024.

Footnote F4

These restricted stock units were assumed by Orthofix in the merger and replaced by 5,399 Orthofix restricted stock units.

Footnote F5

The restricted stock units vest in three equal installments on each of February 28, 2023, 2024 and 2025.

Footnote F6

These restricted stock units were assumed by Orthofix in the merger and replaced by 14,144 Orthofix restricted stock units.

Footnote F7

The option vests as to 25% of the underlying shares on August 1, 2016 and the remaining 75% vests in twelve substantially equal quarterly installments thereafter.

Footnote F8

This option was assumed by Orthofix in the merger and replaced with an option to purchase 24,978 shares of Orthofix at a price of $37.67 per share.

Footnote F9

The option vests as to 12.5% of the underlying shares on August 1, 2016, 6.25% on September 30, 2016 and the remaining 81.25% vests in thirteen substantially equal quarterly installments thereafter.

Footnote F10

This option was assumed by Orthofix in the merger and replaced with an option to purchase 26,892 shares of Orthofix at a price of $34.09 per share.

Footnote F11

The option vests as to 25% of the underlying shares on January 1, 2020 and the remaining 75% in twelve substantially equal quarterly installments thereafter.

Footnote F12

This option was assumed by Orthofix in the merger and replaced with an option to purchase 14,835 shares of Orthofix at a price of $43.82 per share.

Footnote F13

The option vests as to 25% of the underlying shares on January 1, 2021 and the remaining 75% in twelve substantially equal quarterly installments thereafter.

Footnote F14

This option was assumed by Orthofix in the merger and replaced with an option to purchase 11,603 shares of Orthofix at a price of $28.85 per share.

Footnote F15

The option fully vested and became exercisable on June 21, 2020.

Footnote F16

This option was assumed by Orthofix in the merger and replaced with an option to purchase 2,534 shares of Orthofix at a price of $23.86 per share.

Footnote F17

The option vests as to 25% of the underlying shares on January 28, 2022 and the remaining 75% in twelve substantially equal quarterly installments thereafter.

Footnote F18

This option was assumed by Orthofix in the merger and replaced with an option to purchase 6,742 shares of Orthofix at a price of $40.50 per share.

Footnote F19

The option vests as to 25% of the underlying shares on February 28, 2023 and the remaining 75% in twelve substantially equal quarterly installments thereafter.

Footnote F20

This option was assumed by Orthofix in the merger and replaced with an option to purchase 8,840 shares of Orthofix at a price of $36.04 per share.